Discussion
tremor, Tremor, tremors
ADVERSE EVENTS
This was the first randomized pragmatic clinical trial comparing TAPS to SOC in patients with ET, as well as the first randomized TAPS study that included use of TAPS at-home. The study demonstrated that adding TAPS therapy to SOC significantly improved tremor power and BF-ADLs compared to SOC alone during one month of home use, in both the mITT and PP populations (This study demonstrated how motion sensors can be used to measure tremor power over extended home-use and as an endpoint to evaluate the effectiveness of TAPS therapy or other interventions for ET in clinical trials [Motion sensors have been widely used to quantify tremor severity in ET patients [Tremor power improvement measured using motion sensors in this study was slightly lower than previously reported clinical trial findings. In this study, 45% of patients demonstrated tremor power improvement greater than 2-fold (The efficacy and therapy usage can be markedly influenced by the patient selection criteria. For example, a previous study involving a more severe ET population observed a greater improvement in BF-ADL scores with TAPS therapy [Patients with the most severe tremors had the greatest tremor reduction when they received TAPS therapy, which aligns with previous studies [These results are consistent with the growing body of evidence suggesting that TAPS therapy is a safe and effective option for ET patients who are interested in a treatment with less adverse events than current medications and neurosurgical interventions [